

Attorney Docket No.: 9409/2023C  
U.S. Serial No.: 09/939,226  
Filed: August 24, 2001  
Preliminary Amendment  
Page 2 of 6

(d) detecting the presence of any compound specifically bound to said receptor or portion thereof, thereby determining whether said compound specifically binds to said receptor or portion thereof.

51  
62. The method according to claim 61, further comprising the steps of preparing a cell extract from the cell transfected with said nucleic acid molecule, isolating a membrane fraction of said cell extract, and contacting said sample with said membrane fraction under conditions permitting binding of the compound to said fraction.

52  
63. The method according to claim 61, wherein said detecting is performed by monitoring a change in the signaling activity of said CCR5 chemokine receptor or portion thereof.

53  
64. The method according to claim 61, wherein said detecting is performed by monitoring the acidification rate of said host cell.

54  
65. The method according to claim 63, wherein said detecting is performed by monitoring the level of intracellular calcium in said host cell.

55  
66. The method according to claim 63, wherein said detecting is performed by monitoring the stimulation of an intracellular cascade.

56  
67. The method according to claim 63, wherein said detecting is performed by monitoring the level of inositol triphosphate.

57  
68. The method according to claim 61, wherein said compound is an agonist of CCR5.

58  
69. The method according to claim 61, wherein said compound is an antagonist of CCR5.

59  
70. The method according to claim 61, wherein said cell is selected from the group consisting of CHO-K1, HEK293, BHK21, and COS-7.

Attorney Docket No.: 9409/2023C  
U.S. Serial No.: 09/939,226  
Filed: August 24, 2001  
Preliminary Amendment  
Page 3 of 6

60  
71. The method according to claim 61, wherein said cell is exposed to said sample suspected of comprising said compound, in the presence of a ligand for the CCR5 receptor.

61  
72. The method according to claim 71, wherein said ligand which is the CCR5 chemokine is labeled.

62  
73. The method of claim 71, further comprising measuring the infectivity of the cell by HIV.

63  
74. The method according to claim 73, wherein said infectivity of the cell by HIV is measured by measuring the production of an HIV protein.

64  
75. The method according to claim 74, wherein said HIV protein is p24.

65  
76. The method of claim 73 wherein said compound decreases infectivity by HIV by at least two-fold.

66  
77. A method for identifying a compound which specifically binds to the CCR5 chemokine receptor whose amino acid sequence is SEQ ID NO 5, the method comprising the steps of

- (a) transfecting a cell with a nucleic acid molecule encoding said receptor or said portion thereof;
- (b) expressing said receptor or portion thereof under conditions permitting specific binding of said compound to said receptor or portion thereof;
- (c) exposing said cell to said compound; and
- (d) detecting the presence of any compound specifically bound to said receptor or portion thereof, thereby determining whether said compound specifically binds to said receptor or portion thereof.

Attorney Docket No.: 9409/2023C  
U.S. Serial No.: 09/939,226  
Filed: August 24, 2001  
Preliminary Amendment  
Page 4 of 6

67

78. The method according to claim 77, further comprising the steps of preparing a cell extract from the cell transfected with said nucleic acid molecule, isolating a membrane fraction of said cell extract, and contacting said sample with said membrane fraction under conditions permitting binding of the compound to said fraction.

68

79. The method according to claim 77, wherein said detecting is performed by monitoring a change in the signaling activity of said CCR5 chemokine receptor or portion thereof.

69

80. The method according to claim 77, wherein said detecting is performed by monitoring the acidification rate of said host cell.

70

81. The method according to claim 79, wherein said detecting is performed by monitoring the level of intracellular calcium in said host cell.

71

82. The method according to claim 79, wherein said detecting is performed by monitoring the stimulation of an intracellular cascade.

72

83. The method according to claim 79, wherein said detecting is performed by monitoring the level of inositol triphosphate.

73

84. The method according to claim 77, wherein said compound is an agonist of CCR5.

74

85. The method according to claim 77, wherein said compound is an antagonist of CCR5.

75

86. The method according to claim 77, wherein said cell is selected from the group consisting of CHO-K1, HEK293, BHK21, and COS-7.

76

87. The method according to claim 77, wherein said cell is exposed to said compound, in the presence of a ligand for the CCR5 receptor.

Attorney Docket No.: 9409/2023C  
U.S. Serial No.: 09/939,226  
Filed: August 24, 2001  
Preliminary Amendment  
Page 5 of 6

- 77 7b  
88. The method according to claim 87, wherein said ligand which is the CCR5 chemokine is labeled.
- 78 6b  
89. The method of claim 77, further comprising measuring the infectivity of the cell by HIV.
- 79 7a  
90. The method according to claim 89, wherein said infectivity of the cell by HIV is measured by measuring the production of an HIV protein.
- 80 7a  
91. The method according to claim 90, wherein said HIV protein is p24.
- 81 7b  
92. The method of claim 89 wherein said compound decreases infectivity by HIV by at least two-fold.

---

#### REMARKS

Upon entry of this amendment, claims 60-92 are pending. No new matter is introduced by this amendment. Support for the newly added claims may be found in the specification as originally filed and at least at pages 3-8, 10-12, and page 36.